Replay available

BioLineRX (TASE:BLRX) Q1 2021 Earnings Call

BioLineRX (TASE:BLRX) Q1 2021 earnings call, held 2021-05-26. Watch the replay and read the transcript on 6ix.

Wed, May 26, 2021 at 10:00 AMendedReplay
BioLineRX (TASE:BLRX) Q1 2021 Earnings Call
Company
BioLineRX Ltd. (TASE:BLRX)
Period
Q1 2021 earnings call
Date
Wed, May 26, 2021, 10:00 AM ET
Replay
Watch the replay on this page · 19 min

On 6ix: 6ix.com/event/biolinerx-ltd-blrx-q1-2021-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx first quarter 2021 results conference call. All participants are presently in a listen-only mode. Following management's formal presentation, instructions will be given for the question and answer session. For operator assistance during the conference, please press star zero. I would now like to turn over the call to Tim McCarthy of LifeSci Advisors. Please go ahead. Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements in this conference call, other than historical facts, are indeed forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project, and other similar expressions are used typically to identify such forward-looking statements.

0:51 These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other factors that may affect BioLineRx's business, financial condition and other operating results. These include but are not limited to the risk factors and other qualifications contained in BioLineRx's annual report on Form 20F, quarterly reports filed in the 6K and other reports filed by BioLineRx with the SEC to which your attention is directed. Actual outcomes and results may differ materially from what is expressed Thank you, Tim, and good morning, everyone. And thank you for joining us on our first quarter earnings conference call today.

1:47 Earlier this morning we issued our Q1 results press release, a copy of which is available in the investor relations section of our website. It was also filed as a 6K. As is our custom, I will begin with some brief prepared remarks and then Mali Zeevi, our Chief Financial Officer, will provide a short discussion of our financial results. We will then open up the call to your questions. also joining the call for Q&A are Abby Weinstein, our Chief Medical Officer, and Ella Sorani, our Chief Development Officer. Our most meaningful achievement since our last quarterly update is our most recent. Just a few weeks ago, we announced extremely positive top-line results from our Phase III clinical trial, evaluating our lead clinical candidate, Motyxifortide, in stem cell mobilization for multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation.

2:43 Recapping the unmet need, patients undergoing autologous transplantation generally require multiple administrations of GCSF, the current standard of care, and up to four apheresis sessions in order to collect the target number of stem cells required for transplantation. In addition, it is estimated that between 30% and 50% of patients are poor mobilizers. not only necessitating multiple apheresis sessions, but requiring on top of GCSF one to four daily injections of Clorixifor. The main objectives of this study was to demonstrate that Motixifor type on top of GCSF provides superior mobilization relative to the current standard of care, resulting in more cells collected, fewer doses, and fewer apheresis sessions.

3:28 This has significant clinical benefits to patients. Mali Zeevi, Ella Sorani, John Lacey, Philip Serlin, Raziel Fried Since apheresis sessions are costly, so the more days that can be eliminated, the stronger the pharmacoeconomic case to be made for motixifortide as the backbone of a new stem cell mobilization treatment paradigm. To that end, we are currently running a pharmacoeconomic study to support this cost-benefit analysis, which we hope that healthcare payers will ultimately find compelling.

4:14 The data demonstrate that the study successfully met all primary and secondary endpoints, with an exceptionally high level of statistical significance with a p-value of less than 0.0001. Some of the key highlights are 88.3% of patients receiving motixifortide and GCSF underwent transplantation after only one administration of motixifortide and in only one apheresis session. This compares to 10.8% for GCSF alone. Patients receiving metixifortide plus GCSF showed a 54.6% treatment effect and a 4.9-fold increase in the primary endpoint, mobilization of over 6 million cells per kilogram following a single dose of metixifortide in up to two aporesis sessions, as compared to the control arm of GCSF alone.

5:07 While not a head-to-head study, this compares very favorably with to results from the Registrational Study of Plurixifor, which demonstrated a 37.2% treatment effect and a 2.1 fold increase for the Plurixifor plus GCSF arm versus GCSF alone. So to emphasize, a 54.6% treatment effect and 4.9 fold increase in our study versus a 37.2% treatment effect and a 2.1 fold increase in the Plurixifor study in the primary endpoint. The study also achieved its main secondary endpoint, the percentage of patients who mobilized over 6 million cells per kilogram following a single dose of metixifortide on top of GCSF and in just one apheresis session, in an even more impressive manner.

5:58 Patients in the treatment cohort of the Genesis trial demonstrated a 61.7% treatment effect and a 14.1 fold increase as compared to the control arm of GCSF alone. By comparison, the registrational study of Plurixa4 demonstrated a 36.9% treatment effect and a 3.1 fold increase for the Plurixa4 plus GCSF arm versus GCSF alone. Again, to emphasize, a 61.7% treatment effect and a 14.1 fold increase in our study versus a 36.9% treatment effect and a 3.1 fold increase in the Plurixa4 study in the main secondary endpoint. By any measure, we believe these data demonstrate a very significant clinical benefit from adding metixifortide to GCSF and support metixifortide on top of GCSF as the new standard of care mobilization agent in autologous bone marrow transplantation.

6:57 As previously mentioned, this study represents our fastest track to registration. and to that end, we are very diligently working on activities in support of the US New Drug Application or NDA, which we plan to submit in the first half of next year. If ultimately approved in this indication, we would begin our transition to a commercial stage company, the most important and transformational milestone that we will have achieved to date. Turning now to our pancreatic cancer or PDAC program, Recall that in December, we announced positive final results from the Phase 2A Combat Keynote 202 study of Metixifortide in combination with Merck's Anti-PD-1 Keytruda and chemotherapy as a second-line therapy. A total of 43 patients initially diagnosed with unresectable Stage 4 metastatic PDAC who had progressed following first-line gemcitabine-based therapy were enrolled in the triple combination arm.

7:55 Data from this study demonstrated a substantial improvement across all study endpoints as compared to historical data, including median overall survival, median progression-free survival, confirmed overall response rate, overall response rate, and disease control rate. With regard to next steps, as we've previously indicated, we continue to engage in discussions with the potential biopharma partners to collaborate on a randomized controlled Phase 2-3 study. Regarding our second clinical candidate, AGI134, recall that we are evaluating safety, tolerability, and proof of mechanism in multiple solid tumor types in a Phase I-IIa study. The study is designed to evaluate a wide array of biomarkers and assess both clinical and pharmacodynamic parameters. In September 2019, we announced positive safety data, and later that same month, we moved quickly to initiate Part II, the dose expansion phase.

8:52 As we have discussed, the COVID-19 pandemic did impact enrollment for a period of time but has now resumed. We remain on track to report data in the second half of this year. I would now like to turn the call over to Mali Zeevi, our CFO, who will give a brief overview of our key first quarter financial statement items. Mali, please go ahead.

9:13 Thank you, Phil. As is our practice, In our financial discussion, we'll only go over a few significant items on this call, research and development expenses and cash. Therefore, let me invite you to review the filings we made this morning, which contain our financials, operating and financial review, and press release for additional information. Research and development expenses for the quarter ended March 31, 2021, were $4.3 million, a decrease of $1.1 million, compared to $5.4 million for the comparable period in 2020. The decrease resulted primarily from lower expenses associated with the Motexa Fortite Combat Clinical Trial as well as lower expenses associated with the AGI-134 study. Turning to cash, the company held $58.1 million of cash, cash equivalents, and short-term bank deposits, as of March 31, 2021. During the first quarter, we completed a financing that raised gross proceeds of $34.5 million, which we believe will finance the company through multiple potentially value-created milestones.

10:32 And with that, I'll turn the call back over to Phil.

10:36 Thank you, Mali. In closing, as is our custom, I would like to take a few moments to summarize our key upcoming milestones. First, initial results from part two of the phase one two-way trial of AGI-134 in solid tumors in the second half of this year. Also, a pre-NDA meeting with the FDA for stem cell mobilization in the second half of this year, and then an NDA submission for stem cell mobilization in the first half of 2022. Of course, this list does not take into account any potential partnering or strategic transactions. and while we cannot guarantee that a transaction will ultimately come to fruition, discussions with multiple parties are ongoing. In summary, we achieved the most significant milestone in our company's history with the outstanding positive results of the Genesis study in stem cell mobilization.

11:29 We also continue to work on the advancement of our PDAC program as well as AGI 134 and believe that potentially significant value creating milestones can be achieved this year and in 2022. We are pleased with our continued progress and we look forward to providing future updates. With that, we have now concluded the formal part of our presentation. Operator, we will now open up the call to questions. Thank you. Ladies and gentlemen, at this time, we will begin the question and answer session. If you would like to ask a question, please press star 1. To withdraw your question, press star 2. If you are using speaker equipment, kindly lift the handset before pressing the numbers. Your questions will be polled in the order they are received.

12:16 Please stand by while we poll for your questions. The first question is from Joe Pangenis of HC Wainwright.

12:24 Please go ahead. Hi, everyone, and thanks for the update today. Phil, I was just curious, I mean, when you look at your ongoing business development discussions, You obviously have a few things in play with regard to Metixifortide. Ahead of the NDA, you have certain commercial needs and manufacturing needs that you need to put in place, and of course those are not going to be placed on hold, just waiting for any sort of partnering discussions. So I guess, how are you looking at the type of partnership you might want to and the role that a potential partner might want to play in the design of a pancreatic study and in other tumor indications as well.

13:11 Yeah. Hi, Joe. Thanks very much for joining the call. So, you know, it's not necessarily, you know, a given that we would look to partner the indications to the same partner. These are different, you know, these are different players, these are different markets. You know, Hemonc and Solid Tumors. They may interest different parties. We're also looking at potential regional deals as well as global deals. So we also think that it would make sense to potentially separate the two products to have a, you know, Solid Tumor, a chronic indication or administration type product and a one-off product like the Stem Cell Mobilization. And so we're, as we said previously, we're looking for a collaboration partner to continue development in pancreatic cancer.

13:58 The next study, the next step would be a randomized controlled phase two or phase two, three study. We would like to have someone help us finance it, either take it off our hands and move forward themselves in a licensing deal or some type of collaboration. So we are very much working on that. and hope that something will come to fruition sometime, you know, in the near future.

14:23 No, that's good. Thank you. So it definitely sounds like you have important flexibility around this. And then I was just curious regarding, you know, setting expectations for the upcoming update for 1.34. Are you going to be able to generate any sort of translational data at that point?

14:44 Yeah. Hi, Joe. This is Ella. Yes, so definitely. That's the plan. That's the plan to be able to present the pharmacodynamic readouts of the study.

14:59 Actually, I wanted to add what Ella said, that we are actually doing several biopsies and blood tests in the patients that are treated with AGI. The idea is to elucidate and further, you know, understand the biological activity of AGI and confirm the biological activity of AGI as well as to identify whether it's more efficacious or not or have more activity in several tumors.

15:29 Great. Thank you very much. Thanks, Joe. The next question is from Mark Breidenbach of Oppenheimer. Please go ahead.

15:44 Hey, guys. Thanks for taking the questions and congrats on the progress. Just with respect to the pharmacoeconomic study you mentioned, Phil, is that something we might see the results from later this year presented at a conference or separately? And also, can you give us an update on regulatory plans in Europe? Have you talked at all to VMA about the Genesis Phase 3 results? Thanks.

16:12 Okay, so let me take the part about the pharmacoeconomic study. Yeah, so as we mentioned previously, we're deep into the pharmacoeconomic study. We hope that we will have the results of that in the next few months, and we are planning, hopefully, to present it at a scientific conference later in the year.

16:36 Okay, hi, yeah. And you want to take the part? Yes, go ahead. This is Ella. So with regards to our regulatory plans with Europe, in contrary to, you know, we have been discussing the Genesis trial extensively with the FDA. We didn't discuss it with the EMA. Our first priority now is to proceed with the NDA submission, and as Phil stated, we are planning to go to the pre-NDA meeting at the end of this year. So we are focusing currently on that. Having said that, we of course plan also to meet with EMA in order to discuss it as well.

17:19 Okay. Any timing around that plan meeting?

17:23 We don't have the timing yet. I think we feel that it would be important to understand the FDA requirements in the pre-NDA meeting and take that If there are any additional questions, simply press star 1. To withdraw

17:40 your question, press star 2. Please stand by while we poll for more questions. There are no further questions at this time. Before I ask Mr. Phil Serlin to go ahead with his closing statement, I would like to remind participants that a replay of this call is scheduled to begin two hours after the conference. In the US, please call 1-888-295-2634. In Israel, please call 03-9255-904. Internationally, please call 972-392-55904.

18:36 Mr. Serlin, would you like to make your concluding statement?

18:39 Yes, I would. Thank you. That concludes our call this morning. Again, we are extremely pleased with our progress, especially with the outstanding results from the Genesis Phase III trial in stem cell mobilization, which we believe positions metixifortide as the potential future standard of care in this indication, as a one-dose, one-apheresis, and 90% mobilization success regimen. Thank you all very much for your continued interest in BioLineRx and we look forward to providing our next comprehensive update in August. Be safe and have a nice day. Thank you. This concludes the BioLineRx first quarter 2021 conference call. Thank you for your participation. You may go ahead and disconnect.

Follow BioLineRX Ltd. into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Joe Panganis

Analyst, HC Wainwright

Phil Serlin

Chief Executive Officer

Mali Zeevi

Chief Financial Officer

Ella Sorani

Chief Development Officer

Abby Weinstein

Chief Medical Officer

Mark Breidenbach

Analyst, Oppenheimer

More from BioLineRX Ltd.